COVID-19 Vaccines for Young Children
Ages 6 Months – 5 Years

The American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the Advisory Committee on Immunization Practices (ACIP), the Centers for Disease Control and Prevention (CDC) and the North Dakota Department of Health (NDDoH) recommend COVID-19 vaccination for all people ages 6 months and older. The information presented in this handout is compiled to help parents and guardians make an informed decision about COVID-19 vaccination for their children.

What COVID-19 vaccines are available for young children?

The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for COVID-19 vaccines for children ages 6 months through 5 years. Determining which vaccine your child is eligible to receive is dependent on the age of your child on the day of vaccine administration.

<table>
<thead>
<tr>
<th>Moderna COVID-19 Vaccine</th>
<th>Pfizer-BioNTech COVID-19 Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>• For children ages 6 months through 5 years</td>
<td>• For children ages 6 months through 4 years</td>
</tr>
<tr>
<td>• 2-dose primary series</td>
<td>• 3-dose primary series</td>
</tr>
<tr>
<td>• 0 &amp; 28 days apart</td>
<td>• 0, 21, &amp; 81 days apart</td>
</tr>
<tr>
<td>➢ Moderately or severely immunocompromised children should receive an additional (3rd) dose of Moderna at least 28 days after dose 2</td>
<td></td>
</tr>
</tbody>
</table>

Children younger than the age of 5 are not currently authorized to receive a booster dose of COVID-19 vaccine. The NDDoH will notify the public if/when booster doses become available.

COVID-19 Illness & Complications in Young Children

Symptomatic Infection

Children are less likely to develop symptoms if infected with COVID-19, however, there is still the chance that any child could develop symptoms and/or become severely ill due to COVID-19. Additionally, children with underlying health conditions are even more susceptible to experiencing mild to severe symptomatic infection.
➢ As of June 9, 2022, North Dakota has reported **8,457 total positive COVID-19 cases** among children ages 6 months – 4 years.
➢ **61.2%** of those confirmed positive COVID-19 cases in children ages 6 months – 4 years reported experiencing symptoms while infected.
➢ Of those symptomatic cases, the most common symptoms reported were fever (15.8%), chills (4.3%), and myalgia (3.9%).

**Hospitalization**

While most children who contract COVID-19 will experience mild symptoms or no symptoms at all, some children can become severely ill from COVID-19 infection. These children may require hospitalization, intensive care, or a ventilator to help them breathe.

➢ As of June 9, 2022, North Dakota has reported **62 hospitalizations** out of the 8,457 total positive COVID-19 cases among children ages 6 months – 4 years.
➢ North Dakota’s hospitalization rate for children ages 6 months – 4 years is **7.33 children hospitalized per 1,000 positive COVID-19 cases**.
➢ **Nationally**, about half of children hospitalized due to COVID-19 had no underlying medical conditions. Additionally, about one in four children hospitalized were admitted to the intensive care unit (ICU).

**Death**

In rare cases, children who contract COVID-19 may die. Children with underlying health conditions such as asthma, diabetes, or obesity are at increased risk of death due to COVID-19.

➢ North Dakota has reported **1 death** in the 0-5 age group.
➢ In the United States, over 200 children between the ages of 6 months and 4 years have died, making COVID-19 the fifth most common cause of death in children in this age group.

**Multisystem Inflammatory Syndrome (MIS-C)**

COVID-19 infection has also been linked to a rare but serious health condition called multisystem inflammatory syndrome in children (MIS-C). Children who develop MIS-C experience inflammation in different body parts, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. These children may face ongoing health issues due to heart or other organ damage as a result of COVID-19 infection.

➢ As of May 2022, there have been **two cases of MIS-C** reported in North Dakota among children ages 0-5 years.
➢ There have been over **7,880 cases of MIS-C** recorded in the United States, 24% have been reported among children under the age of 5.
➢ MIS-C is more commonly reported among males (61%) and is disproportionately identified in Hispanic and Non-Hispanic Black children.

To learn more about the emergency warning signs and symptoms of MIS-C please visit the link here. It is important that children seek medical attention as soon as possible if they begin to develop symptoms of MIS-C.

Post COVID-19 Conditions (“Long COVID”)

Young children may have trouble describing symptoms of acute COVID-19 infections and post-Covid, so information in this age group is particularly limited. Counts or rates of post-Covid conditions are not available and estimates are best observed nationally. A COVID-19 case in any age group is at risk of developing post-COVID symptoms, though children and adolescents observe the condition less often. Most frequent symptoms of long-Covid in children under the age of 5 include:

- Tiredness or fatigue
- Headache
- Trouble sleeping
- Trouble concentrating
- Muscle and joint pain
- Cough

These symptoms could affect your child’s ability to attend school, daycare, or do their usual activities. If your child is experiencing long-term symptoms, consider speaking with their doctor to discuss their specific needs. One study showed that children ages 0-5 years with COVID-19 infection are more likely than those without COVID-19 infection to experience symptoms (i.e., fatigue, loss of taste, loss of smell) lasting more than four weeks after acute infection.

**What children are at serious risk of COVID-19 illness?**

Certain medical conditions might increase a child’s risk of serious illness with COVID-19, including:

- Obesity
- Diabetes
- Asthma
- Congenital heart disease
- Genetic conditions
- Conditions affecting the nervous system or metabolism

Research also suggests disproportionately higher rates of COVID-19 in Hispanic and non-Hispanic Black children than in non-Hispanic white children (Mayo Clinic).

Updated 6/24/2022
Questions About COVID-19 Vaccines for Young Children

How do COVID-19 vaccines work?

COVID-19 vaccines work similarly to other vaccines. The vaccine stops the virus by helping the immune system make special proteins, called antibodies, to fight the virus.

COVID-19 vaccines are not live virus vaccines and do not alter human DNA.

Are there side effects of COVID-19 vaccines?

Children may experience mild to moderate side effects after receiving a COVID-19 vaccine. Many children will not experience any vaccine side effects. However, during vaccine clinical trials for children of this age group the most common side effects reported after COVID-19 vaccination include pain at the injection site, irritability, drowsiness, and fatigue. Additionally, headache, diarrhea, muscle pain and joint aches were also reported but at lower frequencies. Side effects indicate that the immune system is working and building antibodies to fight the virus.

In rare cases, some young people may experience myocarditis/pericarditis (inflammation of the heart muscle) following a COVID-19 mRNA vaccination. These conditions occur most often in adolescent and young adult males and are typically mild to not life-threatening. Zero cases of myocarditis/pericarditis occurred during Pfizer’s or Moderna’s vaccine clinical trials among children ages 6 months – 5 years.

Are immunocompromised children ages 6 months – 5 years eligible for an additional dose of COVID-19 vaccine?

Determining whether your moderately or severely immunocompromised child is eligible for an additional dose of COVID-19 vaccine is dependent on which vaccine brand (Pfizer or Moderna) they originally received.

- **Moderna**: Moderately or severely immunocompromised children ages 6 months and older who have received 2 doses of Moderna should receive an additional (3rd) dose of Moderna at least 28 days after dose 2.
- **Pfizer**: Moderately or severely immunocompromised children ages 6 months through 4 years who have received 3 doses of Pfizer are not eligible for an additional (4th) dose. However, Pfizer recipients ages 5 and older are eligible for an additional dose of COVID-19 vaccine at least 28 days after dose 2. Please find more information here.
Visit the CDC’s website or talk with your child’s health care provider if you have more questions regarding your child’s medical condition and if they qualify for an additional dose.

**Are children ages 6 months – 5 years eligible for a booster dose of COVID-19 vaccine?**

Depending on the child’s age they may be eligible for a booster dose of COVID-19 vaccine.

- Currently, all children ages 6 months – 4 years are not authorized to receive a booster dose of COVID-19 vaccine.
- All individuals ages 5 years or older should receive a booster dose at least five months after the completion of their primary series, or three months if they are immunocompromised.

More information will be provided if/when booster doses become available for children ages 6 months – 4 years. Moderna confirmed they already started clinical trial testing of a 3rd dose (booster) and will have data by this summer. Please visit the NDDoH Fact Sheet for Children ages 5-11 years for more information on booster doses for children ages 5 years and older.

**Can my child receive the COVID-19 vaccine at the same time as other vaccines?**

Yes. COVID-19 and other vaccines can be administered at the same time. It is recommended that children receive other important vaccines, including those that protect against the flu, whooping cough, tetanus, diphtheria, and measles. Schedule an appointment for your child TODAY to receive their COVID-19 and other routinely recommended vaccines. This is especially important if your child fell behind on immunizations during the pandemic.

**Does my child need COVID-19 vaccination if they have already been infected with COVID-19?**

Yes, CDC recommends that all individuals ages 6 months and older stay up to date on their COVID-19 vaccines even if they have previously tested positive for SARS-CoV-2 (the virus that causes COVID-19). This is because some children may not have mounted the full protection against COVID-19 following their previous infection. Meaning, they do not have the antibodies needed to fight off this virus or other variants of the virus again in the future. Vaccines work to boost the immune system’s response to future infections and protect children from the risk of severe illness, hospitalization, and death due to COVID-19. Additionally, prior infection plus vaccination (hybrid immunity) has been shown to be the best protection in other age groups and is expected to be the best protection among young children as well.

**Are the vaccines for young children effective?**
Yes. The FDA required Moderna and Pfizer to prove immunobridging. This is a process that compares antibodies among this youngest age group to another age group (in this case, those ages 16-25 years) in which the efficacy of a vaccine is already established. Clinical trials found that antibody numbers were comparable to the older age group. In other words, the 2 doses of Moderna and 3 doses of Pfizer worked at building immunity against SARS-CoV-2 in young children.

**About the COVID-19 Vaccine Clinical Trials for Children**

**Highlights from Pfizer’s COVID-19 vaccine clinical trials for children ages 6 months through 4 years of age**

- Pfizer’s pediatric clinical trials included over 4,500 children. Of which, 1,678 children ages 6 months through 4 years were vaccinated during Pfizer’s vaccine trial with a 3 dose primary series.
- The ratio of Pfizer vaccine to placebo vaccine among participants was 2:1.
- Levels of antibodies recorded after dose 3 exceeded those of adults.
- There were 10 symptomatic cases of COVID-19 identified among vaccinated participants within 7 days after the third dose.
- Three doses of the Pfizer-BioNTech COVID-19 vaccine was well-tolerated in this age group, and no new safety signals were identified.
- No hospitalizations due to COVID-19 or cases of MIS-C or myocarditis/pericarditis were reported by any trial participant.
- Some COVID-19 vaccinated children experienced reactions to either dose of the vaccine. Vaccine reactions were more commonly observed after dose 2 and were typically mild to moderate. Common side effects included pain at the injection site, irritability, drowsiness, and fatigue.

**Highlights from Moderna’s COVID-19 vaccine clinical trials for children ages 6 months through 5 years of age**

- Approximately 11,700 children ages 6 months through 12 years were vaccinated during Moderna’s pediatric vaccine trial. Including around 4,200 children ages 2 to under 6 years and around 2,500 children ages 6 months to under 2 years.
- Levels of antibodies recorded after dose 2 were the same or exceeded those in adults.
- No severe adverse events were determined to be related to vaccination in either group. No deaths, no myocarditis or pericarditis, and no multisystem inflammatory syndrome in children (MIS-C) were reported.
- Majority of adverse events were mild or moderate and were more frequently reported after dose two. The most commonly reported symptom was fever and was seen more often after dose two.
• All participants will be monitored for 12 months after their second injection to assess long-term protection and safety.

Please note, efficacy for these two vaccines cannot be directly compared due to the varying length of follow-up, the time period when these studies occurred, which variants were circulating at the time, and the different number of vaccine doses. Both of these vaccines have been shown to reduce the risk of severe illness and death due to COVID-19. They are also expected to decrease hospitalizations and intensive care unit (ICU) stays among this age group. Please speak with a trusted health care provider if you would like more information or help with deciding which COVID-19 vaccine (Pfizer or Moderna) is the best choice for your child.

**Reasons to Vaccinate Young Children Against COVID-19**

• To date, there have been over [2,354,543 million cases](https://www.cdc.gov/coronavirus/2019-ncov/cases-statistics/in-children.html) of COVID-19 among the 0-4 year old population in the United States, making up 3.3% of the United States total cases. Sadly, there have been over [200 deaths](https://www.cdc.gov/coronavirus/2019-ncov/cases-statistics/in-children.html) among the 6 months through 4 years age group in the United States.

• While previous infection can lead to some immunity from COVID-19, vaccination after infection significantly enhances protection and further reduces risk of reinfection. Recent [scientific evidence](https://www.cdc.gov/coronavirus/2019-ncov/cases-statistics/in-children.html) shows that 32% of children failed to make antibodies against SARS-CoV-2 after confirmed infection and had poor T-cell responses. Additionally, Omicron-induced immunity among unvaccinated people does not protect against other variants of concern that may circulate in the future. Fortunately, prior infection plus vaccination (hybrid immunity) has been shown to be the best protection in other age groups and could provide excellent protection in younger age groups as well.

• COVID-19 vaccines are safe, effective, and provide protection from COVID-19 infection, hospitalization, and death. Vaccines are the best way to protect children and prevent serious illness or even death due to COVID-19 disease.

• Fully vaccinated children who are showing no COVID-19 symptoms do not need to quarantine following an exposure to someone infected with COVID-19, this is because their risk of infection is low. Meaning they can continue to attend school, daycare, participate in sports, playdates, and other activities.

• Most children have a grandparent or other person in their lives who are at higher risk of serious illness from COVID-19. Vaccinating all eligible children will help to prevent them from passing COVID-19 to loved ones and other vulnerable people in the community.
• Vaccinating children ages 6 months through 5 years can also help protect family members, including siblings who are immunocompromised and may not mount full protection through vaccination as well as siblings under the age of 6 months who are not yet eligible for vaccination.

**Vaccine Safety Monitoring**

COVID-19 vaccines are being administered under the most intensive vaccine safety monitoring effort in United States History. These web-based platforms give CDC scientists information about the safety of COVID-19 vaccines in real time. If any vaccine safety issues—also called adverse events—are reported, CDC scientists can quickly study them and determine if there is a safety concern with a particular vaccine. Here are some of the tools that CDC uses to keep close tabs on the safety of COVID-19 vaccines:

- **V-safe**: Use your smartphone to tell CDC how you’re feeling after your COVID-19 vaccination and personalized health check-ins to make sure you’re doing well
- **Vaccine Adverse Event Reporting System (VAERS)**: VAERS is the national system that collects reports of adverse events that happen after vaccination.
- **Vaccine Safety Datalink (VSD)**: VSD utilizes data from nine different health systems in the U.S. and compares health and vaccine safety outcomes of those vaccinated to those who are not to determine if the outcome is caused by the vaccine.

**Get Vaccinated Today!**

Children ages 6 months through 5 years can receive their COVID-19 vaccinations at over 100 different locations across North Dakota, including at local public health departments, at family practices, or pediatric clinics. Children age 3 and older can also receive vaccinations through pharmacies. Information on COVID-19 vaccine providers and clinics near you can be found at Vaccines.gov. You can also contact the NDDoH Hotline at 1.866.207.2880 for assistance. As a reminder, COVID-19 vaccines can be administered during the same appointment as other routine immunizations including influenza, MMR, and varicella.

**For more information...**

- [COVID-19 Vaccine Information | NDDoH](#)
- [Pfizer EUA Factsheet (6 months – 4 years) | FDA](#)
- [Moderna EUA Factsheet (6 months – 5 years) | FDA](#)
- [COVID-19 in babies and children - Mayo Clinic](#)
- [For Parents: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 | CDC](#)
• Post-COVID Conditions | CDC
• FDA meeting for <5 COVID vaccine: Q&A - by Katelyn Jetelina (Your Local Epidemiologist)